FDA Warning Letter to Apothecary Pharma Highlights DSCSA Implications for Non-Compliant Compounders

On March 12, 2025, FDA issued a warning letter to Apothecary Pharma, LLC (Scottsdale, AZ) for violations of current good manufacturing practice (cGMP) requirements under 21 CFR Part 211. The letter explicitly connects compounding facility violations to Drug Supply Chain Security Act (DSCSA) obligations — relevant for wholesale drug distributors sourcing from 503B outsourcing facilities that must generate transaction documentation for compounded products entering interstate commerce.

Regulatory Context: 503B Outsourcing Facilities Under DSCSA

503B outsourcing facilities — registered under section 503B of the Federal Food, Drug, and Cosmetic Act — are permitted to compound sterile drugs without individual patient prescriptions, unlike traditional 503A pharmacies. When these facilities distribute compounded products to healthcare facilities or wholesale distributors, they function as trading partners under DSCSA.

The Drug Supply Chain Security Act, enacted in 2013, requires all entities in the pharmaceutical supply chain to provide transaction information (TI), transaction history (TH), and transaction statement (TS) — collectively known as the "3Ts" — for product transfers. As of November 27, 2024, enhanced drug distribution security requirements took effect. Outsourcing facilities distributing compounded drugs through the wholesale channel must comply with DSCSA's serialization and tracing requirements for products that qualify as "prescription drugs" under the act.

The FDA's March 2025 warning letter is notable because it directly references DSCSA compliance expectations when citing Apothecary Pharma's failure to maintain adequate documentation systems for batch records and distribution tracking.

Key Violations in the Warning Letter

FDA's inspection of Apothecary Pharma identified three primary deficiencies relevant to wholesale distribution compliance:

1. Inadequate batch production and control records (21 CFR 211.188) — The facility failed to maintain complete batch records for compounded products, including documentation of component lot numbers, expiration dates, and quality control testing results.

1. Failure to implement adequate written procedures for distribution (21 CFR 211.150) — FDA cited the lack of documented procedures for verifying that finished drug products were distributed under conditions that ensure product integrity and chain of custody.

1. Inadequate investigation of distribution discrepancies — The warning letter noted that Apothecary Pharma did not adequately investigate instances where products were shipped to entities not authorized to receive them, raising DSCSA "authorized trading partner" verification concerns.

The letter states: "Your firm's failure to maintain adequate records and procedures creates gaps in the ability to trace products through the supply chain, which directly undermines DSCSA's serialization and tracing objectives."

Impact on Wholesale Drug Distributors

Wholesale distributors sourcing from 503B outsourcing facilities should verify that their compounding partners maintain cGMP compliance and proper DSCSA documentation systems. Specific operational considerations:

Transaction documentation verification — Distributors receiving compounded products from outsourcing facilities must confirm the supplier can provide complete transaction information, including product identifiers, quantities, dates, and involved parties. Facilities under FDA warning for inadequate record-keeping may be unable to furnish compliant TI/TH/TS.

Authorized trading partner status — Under DSCSA, distributors must only transact with authorized trading partners. A 503B facility subject to FDA enforcement action for distribution control failures presents elevated risk in ATP verification workflows.

Due diligence documentation — For audits and regulatory inspections, distributors should retain evidence of supplier qualification activities, including verification that compounding sources hold active FDA 503B registration and maintain cGMP compliance. FDA warning letters represent a negative compliance signal requiring documented risk assessment.

Product recall implications — Compounded products distributed without adequate batch documentation create traceability gaps. In a recall scenario, distributors may be unable to identify affected lots or notify downstream customers, violating DSCSA's tracing requirements under 21 USC 360eee-1.

The Apothecary Pharma warning letter underscores that FDA views inadequate documentation at compounding facilities as a supply chain integrity issue, not solely a manufacturing deficiency. Distributors must incorporate 503B outsourcing facility compliance into vendor qualification and ongoing monitoring processes.

What ColdChainCheck Data Shows

ColdChainCheck currently tracks 1,275 wholesale drug distributors and 3PLs, but does not separately index 503B outsourcing facilities as a distinct entity category. However, the compliance signals relevant to the Apothecary Pharma warning letter — FDA registration status, enforcement actions, and documentation practices — apply to any supplier that functions as a DSCSA trading partner.

Of the 1,234 entities in our directory with verified FDA registration, 73 have at least one FDA recall, warning letter, or enforcement action on record. This represents 5.9% of registered entities with documented negative compliance signals. For wholesale distributors conducting supplier qualification, this baseline rate provides context: a 503B outsourcing facility with an active FDA warning letter falls outside normal risk parameters.

The average compliance score across all tracked entities is 51/100, placing the typical distributor in the "Fair" tier. Only 28 entities (2.2%) achieve "Excellent" scores of 90 or above — reflecting the difficulty of maintaining comprehensive, publicly verifiable compliance signals across state licensure, federal registration, and industry accreditation programs. Compounding facilities face similar documentation burdens; inadequate record-keeping systems compound (no pun intended) as DSCSA requirements expand.

Practical Steps for Compliance Teams

Wholesale distributors sourcing from 503B outsourcing facilities should take the following actions in response to the Apothecary Pharma warning letter:

• Cross-reference supplier FDA registration — Use the ColdChainCheck directory to verify that compounding sources hold active FDA Establishment Registration. While ColdChainCheck does not currently track 503B facilities specifically, distributors can manually search FDA's Registered Outsourcing Facilities database and document verification as part of supplier qualification files.

• Review transaction documentation workflows — Audit recent transactions with outsourcing facilities to confirm receipt of complete TI/TH/TS. If a supplier cannot produce lot-level documentation matching shipment records, this represents a DSCSA compliance gap requiring escalation to QA leadership.

• Monitor FDA warning letter database — Add FDA's Warning Letters page (filtered for "compounding" or "503B") to quarterly compliance monitoring checklists. ColdChainCheck tracks enforcement actions for wholesale distributors; compliance teams should apply the same monitoring discipline to compounding suppliers.

• Document supplier risk assessments — For any 503B facility under FDA enforcement action, create a written risk assessment evaluating the entity's ability to meet DSCSA obligations. This documentation supports due diligence in the event of a downstream audit or product quality issue.

ColdChainCheck will continue monitoring FDA enforcement activity affecting pharmaceutical supply chain participants. For broader guidance on DSCSA compliance signals, see our DSCSA Compliance Guide.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult qualified legal counsel and review applicable federal and state regulations when evaluating supplier compliance obligations.